Posted by Michael Wonder on 11 Dec 2019
Decision to award sole supply for apomorphine hydrochloride
11 December 2019 - PHARMAC are pleased to announce changes to the funding of apomorphine hydrochloride, a medicine used to treat advanced Parkinson’s disease, through an agreement with Stada.
In summary:
- The Movapo brand of apomorphine 10 mg per ml, 2 ml ampoule will remain funded.
- A new apomorphine 10 mg/mL, 5 mL ampoule will be funded from 1 February 2020.
- Consumables for continuous infusion and intermittent injection will be available to patients free of charge from 1 January 2020.
- The infusion pump will continue to be supplied to patients, on loan, free of charge and patients will continue to receive the education and nursing support service provided by Stada.
- the cost of Movapo 2 mL ampoule will be reduced from 1 January 2020 and Movapo will be the only funded brand of apomorphine hydrochloride until 30 June 2023.
Read PHARMAC Consultation
Posted by:
Michael Wonder